Greenwich LifeSciences Accelerates Patient Screening in FLAMINGO-01 Trial
Event summary
- Greenwich LifeSciences increased patient screening rate to over 800 patients per year, a 33% rise from prior 600 patients annually.
- Non-HLA-A*02 arm of FLAMINGO-01 trial is fully enrolled with 250 patients treated with GLSI-100.
- Preliminary data shows approximately 80% reduction in recurrence rate after Primary Immunization Series (PIS).
- FLAMINGO-01 trial now includes US and European clinical sites from university-based hospitals.
The big picture
Greenwich LifeSciences' operational improvements in patient screening reflect growing momentum in its Phase III trial for GLSI-100, an immunotherapy targeting breast cancer recurrence. The company's ability to expand site activation and maintain high enrollment rates positions it favorably within the competitive landscape of oncology treatments. Successful validation of preliminary data could significantly impact treatment paradigms for HER2-positive breast cancer patients.
What we're watching
- Trial Momentum
- Whether the current screening rate acceleration can be sustained or further improved as additional sites are activated.
- Data Validation
- How preliminary recurrence rate reductions will compare to final study results and whether they align with Phase IIb trial outcomes.
- Regulatory Pathway
- The pace at which FLAMINGO-01 data could support potential regulatory approvals for GLSI-100 in preventing breast cancer recurrences.
Our editorial coverage:
Related topics